Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease.
OBJECTIVE
Recent data suggest functional interactions between NOD2 and other receptors of the innate immune system modulating inflammatory responses. Here we analyzed the role of Toll-like receptor 9 (TLR-9) gene variants with respect to susceptibility to inflammatory bowel disease (IBD) and tested for genetic interactions with NOD2 and other susceptibility genes for Crohn's disease (CD).


METHODS
The single-nucleotide polymorphisms (SNPs) -1237T/C (rs5743836) and 2848A/G (rs352140=p.Pro545Pro) in TLR9, the main CD-associated variants within the genes for NOD2, IL23R, ATG16L1, and variants in the IBD5 locus and in the DLG5 gene were assessed in 956 patients with IBD (606 CD and 350 ulcerative colitis) and in 792 healthy controls. The associations with disease susceptibility and phenotype, and epistatic gene-gene interactions, were analyzed.


RESULTS
The TLR9 -1237T/C polymorphism showed significant interactions with NOD2 mutations. The frequency of -1237C was significantly higher in CD patients with at least one NOD2 mutation (P=0.004 vs. controls, odds ratio (OR) 1.60, 95% confidence interval (CI) (1.15-2.21)) and further increased in CD patients with two mutated NOD2 alleles (P=0.002 vs. controls, OR 2.37, 95% CI (1.35-4.15)). Significant gene-gene interactions were also observed for the TLR9 polymorphism -1237T/C with IL23R variants (most significantly with rs1004819, P=0.0007), with a particular high frequency of -1237C in CD patients carrying CD-protective IL23R variants. Epistatic interactions of the TLR9 -1237T/C SNP were also noted with the DLG5 113G/A variant (P=0.0007).


CONCLUSIONS
Our results provide evidence for genetic interactions between polymorphisms in TLR9 and CD-associated variants in NOD2, IL23R, and DLG5, differentially modulating CD susceptibility.
Török
Helga P
HP
Department of Internal Medicine II, Campus Grosshadern, University of Munich, Munich, Germany. helga.toeroek@med.uni-muenchen.de
Glas
Jürgen
J
Endres
Ilona
I
Tonenchi
Laurian
L
Teshome
Molla Y
MY
Wetzke
Martin
M
Klein
Wolfram
W
Lohse
Peter
P
Ochsenkühn
Thomas
T
Folwaczny
Matthias
M
Göke
Burkhard
B
Folwaczny
Christian
C
Müller-Myhsok
Bertram
B
Brand
Stephan
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D016022:Case-Control Studies; D003093:Colitis, Ulcerative / Q000453:epidemiology / Q000235:genetics / Q000503:physiopathology; D003424:Crohn Disease / Q000453:epidemiology / Q000235:genetics* / Q000503:physiopathology; D004843:Epistasis, Genetic; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology*; D014644:Genetic Variation; D055106:Genome-Wide Association Study; D005858:Germany; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011336:Probability; D011379:Prognosis; D018123:Receptors, Interleukin / Q000235:genetics*; D012016:Reference Values; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D051217:Toll-Like Receptor 9 / Q000235:genetics*; D055815:Young Adult
C515500:IL23R protein, human; D053473:Nod2 Signaling Adaptor Protein; D018123:Receptors, Interleukin; D051217:Toll-Like Receptor 9